Mipomersen (DrugBank: Mipomersen)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 79 | Homozygous familial hypercholesterolemia | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00607373 (ClinicalTrials.gov) | July 2007 | 22/1/2008 | Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects | Lipid Metabolism, Inborn Errors;Hypercholesterolemia, Autosomal Dominant;Hyperlipidemias;Metabolic Diseases;Hyperlipoproteinemia Type II;Metabolism, Inborn Errors;Genetic Diseases, Inborn;Infant, Newborn, Diseases;Metabolic Disorder;Congenital Abnormalities;Hypercholesterolemia;Hyperlipoproteinemias;Dyslipidemias;Lipid Metabolism Disorders | Drug: mipomersen;Drug: Placebo | Kastle Therapeutics, LLC | Ionis Pharmaceuticals, Inc. | Completed | 12 Years | N/A | All | 51 | Phase 3 | United States;Brazil;Canada;Singapore;South Africa;Taiwan;United Kingdom;Netherlands |